Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada

Annals of Clinical Microbiology and Antimicrobials

Volumn 9, Issue , 2010, Pages

  Patel, Samir N ^a,b,c   Melano, Roberto ^a,b,c   McGeer, Allison ^a,b   Green, Karen ^b   Low, Donald E ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE IV; QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CANADA; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECT; GENE FREQUENCY; GENETICS; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MUTATION; PNEUMOCOCCAL INFECTION;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; CANADA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENE FREQUENCY; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 76949085586     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-9-3     Document Type: Article

References (40)

1. Loeb M. Pneumonia in older persons. Clin Infect Dis 2003, 37(10):1335-1339. 10.1086/379076, 14583867.
2. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992, 14(4):801-807.
3. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008, 6(4):288-301. 10.1038/nrmicro1871, 18340341.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG, . Infectious Diseases Society of America; American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72. 10.1086/511159, 17278083, Infectious Diseases Society of America; American Thoracic Society.
5. Fuller JD, McGeer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis 2005, 24(12):780-788. 10.1007/s10096-005-0059-x, 16344922.
6. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009, 34(1):82-85. 10.1016/j.ijantimicag.2009.02.002, 19342204.
7. Patel SN, McGeer A, Green K, Low DE, . Canadian Bacterial Surveillance Network (CBSN) Lack of emergence of gyrA mutations in S. pneumoniae (SP) despite increased fluoroquinolone (FQ) usage. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Disease of Society of America 46th Annual Meeting: 2008; Washington, DC (Abstract # C2-1843), Canadian Bacterial Surveillance Network (CBSN).
8. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005, 65(7):949-991. 10.2165/00003495-200565070-00004, 15892589.
9. Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005, 33(3):106-114. 10.1007/s15010-005-4102-8, 15940410.
10. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, de Azavedo JC. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000, 44(11):3049-3054. 10.1128/AAC.44.11.3049-3054.2000, 101601, 11036021.
11. Bush K, Goldschmidt R. Effectiveness of fluoroquinolones against gram-positive bacteria. Curr Opin Investig Drugs 2000, 1(1):22-30.
12. Heaton VJ, Ambler JE, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother 2000, 44(11):3112-3117. 10.1128/AAC.44.11.3112-3117.2000, 101612, 11036032.
13. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect 2005, 11(4):256-280. 10.1111/j.1469-0691.2005.01131.x, 15760423.
14. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003, 51(Suppl 1):29-35. 10.1093/jac/dkg207, 12702701.
15. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother 2002, 49(6):893-895. 10.1093/jac/dkf047, 12039880.
16. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000, 45(5):583-590. 10.1093/jac/45.5.583, 10797078.
17. Fisher LM, Heaton VJ. Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2003, 51(2):463-464. author reply 464-465, 10.1093/jac/dkg059, 12562724.
18. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999, 43(2):410-412. 89092, 9925547.
19. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997, 41(2):471-474. 163733, 9021211.
20. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998, 42(11):2810-2816. 105948, 9797208.
21. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother 2002, 46(2):413-419. 10.1128/AAC.46.2.413-419.2002, 127068, 11796351.
22. Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2009, 63(3):443-450. 10.1093/jac/dkn528, 19147516.
23. Korzheva N, Davies TA, Goldschmidt R. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 2005, 49(6):2479-2486. 10.1128/AAC.49.6.2479-2486.2005, 1140505, 15917550.
24. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005, 40(2):225-235. 10.1086/426817, 15655739.
25. Adam HJ, Schurek KN, Nichol KA, Hoban CJ, Baudry TJ, Laing NM, Hoban DJ, Zhanel GG. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007, 51(1):198-207. 10.1128/AAC.00609-06, 1797689, 17088485.
26. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999, 43(2):329-334. 89072, 9925527.
27. Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, Kohrer K, Schmitz FJ. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 2000, 44(2):462-466. 10.1128/AAC.44.2.462-466.2000, 89708, 10639387.
28. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother 2000, 44(2):304-310. 10.1128/AAC.44.2.304-310.2000, 89675, 10639354.
29. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996, 40(12):2760-2764. 163617, 9124836.
30. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996, 40(10):2252-2257. 163513, 8891124.
31. Reinert RR, Al-Lahham A, Lutticken R, Boos M, Schmitz FJ. Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. J Antimicrob Chemother 2002, 49(6):1015-1018. 10.1093/jac/dkf036, 12039895.
32. Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, Tateyama M, Nakasone I, Yamane N, Fujita J. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 2006, 58(6):1279-1282. 10.1093/jac/dkl427, 17056610.
33. Lovgren M, Spika JS, Talbot JA. Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992-1995. Cmaj 1998, 158(3):327-331. 1228832, 9484256.
34. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI document M7-A7. 2006, Wayne, PA; CLSI, Clinical and Laboratory Standards Institute (CLSI).
35. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement. CLSI document M100-S16. 2007, Wayne, PA; CLSI, Clinical and Laboratory Standards Institute (CLSI).
36. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002, 346(10):747-750. 10.1056/NEJMoa012122, 11882730.
37. Anderson KB, Tan JS, File TM, DiPersio JR, Willey BM, Low DE. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003, 37(3):376-381. 10.1086/376642, 12884162.
38. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, Beekmann S. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 2005, 41(2):139-148. 10.1086/430906, 15983908.
39. Orscheln RC, Johnson DR, Olson SM, Presti RM, Martin JM, Kaplan EL, Storch GA. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J Infect Dis 2005, 191(8):1272-1279. 10.1086/428856, 15776373.
40. Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother 2006, 57(3):437-442. 10.1093/jac/dki487, 16431861.